China-based PrimeGene has submitted a listing application to the Hong Kong Stock Exchange (HKEX). Founded in 2016, the company is a biotechnology firm focusing on immune-inflammatory diseases, with a goal of becoming a leader in locally delivered targeted therapies. Its lead asset is pumecitinib, a JAK1/JAK2 inhibitor developed in both gel and a nasal spray formulations. The gel, intended for atopic dermatitis, has completed a Phase III trial, and the company plans to submit a new drug application (NDA) in the first quarter of 2026.

The nasal spray formulation, for seasonal allergic rhinitis, is currently in Phase III development, with a new drug application anticipated in Q4 2026. PrimeGene's pipeline also includes other candidates with first-in-class potential. The company reported R&D expenses of approximately RMB 97 million for the first nine months of 2025.

According to PharmCube's MedAlpha® database, PrimeGene has raised over USD 70 million in four pre-IPO funding rounds. Click here to request a free trial for MedAlpha®.